1-2017-K9 is a multicenter, randomized clinical safety and efficacy study to evaluate the safety and efficacy of StablePlate RX® in clinical canine patients for the control of life threatening hemorrhage secondary to thrombocytopenia. For more information please contact BodeVet.

For more information, click here.

The in-human care population of elephants is plagued by an endotheliotropic herpes virus that attacks young elephants and causes an acute loss of platelets with associated bleeding. BodeVet, Inc. working with the Smithsonian Institute has begun the process of producing lyophilized platelets for zoos to have available when bleeding occurs. A clinical trial is proposed to determine if platelet transfusion improves outcome, saving these magnificent animals from death.

Click here to read the full article!

JAVMA - Vol 252 - No. 2 - Januar 15, 2018

BodeVet, Inc. will have a booth at the ACVIM exhibit hall in Seattle WA on June 12th to 15th! Please come visit us to hear about our freeze dried platelet product.

ACVIM 2018 - Seattle WA

BodeVet Chief Technical officer, Anne Hale, DVM, will advise on controversies in blood banking at the International Veterinary Emergency and Critical Care Symposium (IVECCS) 2017. As a recognized world leader in veterinary blood banking, Anne Hale joins a selection of other experts for a panel discussion. This discussion is open to all IVECCS attendees and takes place at 4:15 pm on Friday, September 15.

IVECCS 2017

This September, the world’s first injectable freeze-dried platelet derived product will be StablePlate RX™ for canines. StablePlate RX™ is a shelf stable hemostatic agent that couples the healing power of platelets with the stability and convenience of other medicines. BodeVet will release StablePlate RX™ on a limited basis at the International Veterinary and Critical Care Symposium (IVECCS). Visit BodeVet at IVECCS at Booth 502.

StablePlate RX™

IVECCS 2017

Thanks to a grant from the International Elephant Foundation, biotechnology company Cellphire, Smithsonian Global Health Program, Ringling Bros. Center for Elephant Conservation, Fort Worth Zoo, and Houston Zoo have made great strides in developing a novel treatment for a lethal virus afflicting baby Asian elephants around the globe. Elephant Endotheliotropic Herpesvirus (EEHV) is the leading cause of death among captive Asian elephants under 12 years of age. EEHV attacks blood vessels and frequently causes uncontrolled hemorrhage, causing the victim to die of blood loss.

The innovative treatment under development builds off of cutting-edge research in human platelet-products, a specialty of Cellphire. This ground-breaking treatment is shelf-stable and can stop bleeding from trauma and internal damage. The human product is targeted at situations as diverse as battlegrounds and Ebola outbreaks. Until now, there has not been a version for elephants. The biotech firm is aided by the extensive elephant health expertise from partner zoological veterinarians at diverse institutions. To date, blood from two Asian Elephants has been collected, stabilized, and prepared for separation into component parts. Separation was successful, and scientists isolated platelet-rich plasma, which was then freeze-dried using a proprietary process. The resulting lyophilized platelets are being subjected to a battery of quality control tests to evaluate shape, size, identity, activity, and purity. So far, the platelet product reconstitutes appropriately and contains adequate size and number of particles. Samples have been tested for sterility, and the product meets or exceeds FDA regulations for an injectable blood product’s sterility. The product also passes tests for bacterial endotoxin. Partners are currently focused on optimizing protocols to appropriately utilize antibodies for confirmation of identity and purity. Assessing in vitro potency for activation and clot formation. These complicated laboratory procedures are designed to ensure that the final result is a treatment that is safe, effective, and reliable as a treatment for stopping the dangerous hemorrhage caused by EEHV.

Announcement from Smithsonian’s National Zoo & Conservation Biology Institute

The 1-2017-K9 trial for StablePlate RX™ is underway. StablePlate RX™ is being evaluated in canines with life-threatening bleeding secondary to thrombocytopenia. Safety and efficacy results are anticipated in fall 2017.

BodeVet is working with top veterinarians at academic and private hospitals to advance the standard of care for veterinary patients. StablePlate RX™ stands to revolutionize bleeding management – it is derived from the perishable blood cells that naturally stop bleeding, platelets. As a dry powder, StablePlate RX™ is a controlled, shelf-stable, and easy-to-use platelet substitute.

BodeVet expects that this pivotal trial for StablePlate RX™ may have implications in informing and galvanizing future trials, which may qualify StablePlate RX™ for use in more indications in more animals, or qualify entirely new products.

The healing properties of platelets extend beyond bleeding management, which leaves BodeVet excited to explore further veterinary applications for its platelet-derived products.

The Grayson-Jockey Club has awarded a two year-grant to the University of North Carolina for equine platelet research. The study will examine the antibacterial properties of platelets in treating horses with joint infections, and measure the effect of platelet lysate therapy on morbidity and mortality. The grant funds were awarded as part of a larger, $1,478,542 effort in 2017 to advance the equine industry for the betterment of all horses.

“…We recently found that platelet-rich plasma (PRP), a therapy commonly used to help recovery from athletic injuries, is useful in fighting off bacterial infections.”

-Lauren Schnabel, North Carolina State University, www.grayson-jockeyclub.org

“…many hospitalized foals have low platelet counts, referred to as thrombocytopenia, associated with their illnesses.”

-Stace Oke, DVM, MSc, www.TheHorse.com